News from synthetic biologics, inc

Jul 21, 2014, 06:58 ET
Synthetic Biologics, Inc. Logo.  (PRNewsFoto/Synthetic Biologics, Inc.)

Synthetic Biologics' Academic Collaborator to Present Novel Monoclonal Antibody Combination for Treating Whooping Cough (Pertussis) at Gordon Research Conference

Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of novel anti-infective biologic and drug candidates targeting specific pathogens that cause...

Jun 30, 2014, 06:57 ET
Synthetic Biologics, Inc. Logo.  (PRNewsFoto/Synthetic Biologics, Inc.)

Synthetic Biologics Forms Clinical Advisory Board to Support Novel C. difficile Preventative Program

 Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of novel anti-infective biologic and drug candidates targeting specific pathogens that...

Jun 25, 2014, 06:57 ET
Synthetic Biologics, Inc. Logo.  (PRNewsFoto/Synthetic Biologics, Inc.)

Synthetic Biologics Reports that Licensor Cedars-Sinai Finds Eradication of Gut Methane Improves Insulin Sensitivity and Lipid Profiles in Study of Pre-Diabetic, Obese Patients

ROCKVILLE, Md., June 25, 2014 /PRNewswire/ -- Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of novel anti-infective biologic and drug...

Jun 10, 2014, 03:00 ET
Synthetic Biologics, Inc. Logo.  (PRNewsFoto/Synthetic Biologics, Inc.)

Synthetic Biologics and Enterome Bioscience Collaborate on Microbiome Research to Support Synthetic Biologics' C. difficile Program

 Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of novel anti-infective biologic and drug candidates targeting specific pathogens that...

May 20, 2014, 14:48 ET
Synthetic Biologics, Inc. Logo.  (PRNewsFoto/Synthetic Biologics, Inc.)

Synthetic Biologics to Present at the 3rd Annual Marcum LLP MicroCap Conference

 Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of anti-infective biologic and drug candidates targeting specific pathogens that cause...

May 15, 2014, 06:56 ET
Synthetic Biologics, Inc. Logo.  (PRNewsFoto/Synthetic Biologics, Inc.)

Synthetic Biologics Reports First Quarter 2014 Financial Results and Operational Highlights

 Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of novel anti-infective biologic and drug candidates targeting specific pathogens that...

May 09, 2014, 06:57 ET
Synthetic Biologics, Inc. Logo.  (PRNewsFoto/Synthetic Biologics, Inc.)

Synthetic Biologics to Report First Quarter 2014 Financial Results

Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of novel anti-infective biologic and drug candidates targeting specific pathogens that cause...

May 08, 2014, 06:58 ET
Synthetic Biologics, Inc. Logo.  (PRNewsFoto/Synthetic Biologics, Inc.)

Synthetic Biologics Announces Recent International Patents that Bolster its C. difficile Program

 Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of novel anti-infective biologic and drug candidates targeting specific pathogens that...

Apr 30, 2014, 06:58 ET
Synthetic Biologics, Inc. Logo.  (PRNewsFoto/Synthetic Biologics, Inc.)

Synthetic Biologics to Discuss Phase II Results of Oral Estriol Candidate Trimesta™ for Relapsing-Remitting Multiple Sclerosis in Women

 Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of novel anti-infective biologic and drug candidates targeting specific pathogens that...

Apr 29, 2014, 15:45 ET
Synthetic Biologics, Inc. Logo.  (PRNewsFoto/Synthetic Biologics, Inc.)

Synthetic Biologics Reports UCLA Announcement of Preliminary Positive Topline Efficacy and Safety Results from Investigator-Led Phase II Study of Trimesta™ for Relapsing-Remitting Multiple Sclerosis

Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of novel anti-infective biologic and drug candidates targeting specific pathogens that cause...

Apr 23, 2014, 07:00 ET
Synthetic Biologics, Inc. Logo.  (PRNewsFoto/Synthetic Biologics, Inc.)

Synthetic Biologics' Reports Preclinical Data to Support Clinical Development of Novel Pertussis Therapeutic

 Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of novel anti-infective biologic and drug candidates targeting specific pathogens that...

Apr 14, 2014, 07:00 ET
Synthetic Biologics, Inc. Logo.  (PRNewsFoto/Synthetic Biologics, Inc.)

Synthetic Biologics Appoints Mark Pimentel, M.D., Chairman of New Irritable Bowel Syndrome Clinical Advisory Board

ROCKVILLE, Md., April 14, 2014 Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of novel anti-infective biologic and drug candidates...

Mar 31, 2014, 07:00 ET
Synthetic Biologics, Inc. Logo.  (PRNewsFoto/Synthetic Biologics, Inc.)

Synthetic Biologics Reports Year End 2013 Financial Results and Operational Update

 Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of novel anti-infective biologic and drug candidates targeting specific pathogens that...

Mar 25, 2014, 11:17 ET
Synthetic Biologics, Inc. Logo.  (PRNewsFoto/Synthetic Biologics, Inc.)

Synthetic Biologics to Report Year End 2013 Financial Results

Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of novel anti-infective biologic and drug candidates targeting specific pathogens that cause...

Mar 10, 2014, 07:00 ET
Synthetic Biologics, Inc. Logo.  (PRNewsFoto/Synthetic Biologics, Inc.)

Synthetic Biologics Announces Issuance of U.S. Patent Adding Another Layer of Protection for the Use of Oral Estriol Candidate, Trimesta™, for Multiple Sclerosis

Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of anti-infective biologic and drug candidates targeting specific pathogens that cause...

Mar 05, 2014, 07:00 ET
Synthetic Biologics, Inc. Logo.  (PRNewsFoto/Synthetic Biologics, Inc.)

Synthetic Biologics to Present at the 26th Annual ROTH Conference

Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of anti-infective biologic and drug candidates targeting specific pathogens that cause...

Feb 26, 2014, 17:01 ET
Synthetic Biologics, Inc. Logo.  (PRNewsFoto/Synthetic Biologics, Inc.)

Synthetic Biologics' Board of Directors Accepts Resignation of Long-Standing Founder and Board Member

 Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of anti-infective biologic and drug candidates targeting specific pathogens that cause...

Feb 13, 2014, 15:57 ET

Synthetic Biologics, Inc. States that Its Policy is Not to Comment on Unusual Market Activity

 Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of product candidates focused on the prevention and treatment of serious infectious and...

Feb 10, 2014, 07:00 ET

Synthetic Biologics Announces Rhonda Voskuhl, M.D., to Present Trimesta™ Phase II Multiple Sclerosis Clinical Trial Results at the 2014 AAN Annual Meeting

Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of product candidates focused on the prevention and treatment of serious infectious and...

Feb 04, 2014, 07:00 ET

Synthetic Biologics to Present at the 2014 BIO CEO & Investor Conference

Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of product candidates focused on the prevention and treatment of serious infectious and...

Organizations in the News

The organizations with the most activity in PR Newswire's News Room

Research and Markets
ReportBuyer
Investor-Edge